MRKR Marker Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MRKR

Price (delayed)

$1.48

Market cap

$24.68M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.61

Enterprise value

$9.04M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 32

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy ...

Highlights
The EPS has soared by 54% year-on-year and by 23% since the previous quarter
MRKR's net income is up by 15% year-on-year and by 10% since the previous quarter
Marker Therapeutics's quick ratio has decreased by 42% from the previous quarter and by 28% YoY
Marker Therapeutics's gross profit has decreased by 40% YoY and by 10% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://markertherapeutics.com
Peers: VIVS ORIC ORMP

Key stats

What are the main financial stats of MRKR

MRKR stock price

How has the Marker Therapeutics stock price performed over time
Intraday
2.07%
1 week
-1.99%
1 month
-5.13%
1 year
-1.99%
YTD
-0.67%
QTD
13.85%

Financial performance

How have Marker Therapeutics's revenue and profit performed over time
Revenue
$3.2M
Gross profit
$3.2M
Operating income
-$12.35M
Net income
-$10.9M
Gross margin
100%
Net margin
-340.8%
MRKR's operating margin has dropped by 53% year-on-year and by 6% since the previous quarter
The company's net margin fell by 43% YoY
Marker Therapeutics's gross profit has decreased by 40% YoY and by 10% QoQ
MRKR's revenue is down by 40% year-on-year and by 10% since the previous quarter

Price vs fundamentals

How does MRKR's price correlate with its fundamentals

Growth

What is Marker Therapeutics's growth rate over time

Valuation

What is Marker Therapeutics stock price valuation
P/E
N/A
P/B
1.79
P/S
8.94
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.83
The EPS has soared by 54% year-on-year and by 23% since the previous quarter
The P/B is 35% above the last 4 quarters average of 1.3 but 13% below the 5-year quarterly average of 2.0
Marker Therapeutics's equity has decreased by 18% from the previous quarter and by 4.8% YoY
MRKR's P/S is 59% above its last 4 quarters average of 5.5 but 18% below its 5-year quarterly average of 10.7
MRKR's revenue is down by 40% year-on-year and by 10% since the previous quarter

Efficiency

How efficient is Marker Therapeutics business performance
The ROS is down by 43% year-on-year
The ROE is up by 28% year-on-year and by 9% since the previous quarter
The ROA has grown by 28% YoY and by 11% from the previous quarter

Dividends

What is MRKR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MRKR.

Financial health

How did Marker Therapeutics financials performed over time
MRKR's total liabilities has surged by 60% since the previous quarter and by 45% year-on-year
The current ratio has contracted by 43% from the previous quarter and by 29% YoY
The company's debt is 100% lower than its equity
Marker Therapeutics's equity has decreased by 18% from the previous quarter and by 4.8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.